HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?

Despite the recent “feeding frenzy,” Pitchbook’s Ben Zercher told Fierce he expects in vivo CAR-T dealmaking to slow due to a shortage of viable acquisition targets.

By FierceBiotech · Apr 25, 2026 · via FierceBiotech
After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
dealsformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Lilly Spends Up to $3.8B on Three Vaccine Developers
DealsBriefing
Lilly Spends Up to $3.8B on Three Vaccine Developers
The pharma giant’s latest acquisitions of Curevo, LimmaTech, and Vaccine Company reinforce its pivot from trea…
May 26, 2026
Medtronic inks $650M deal for SPR Therapeutics
DealsFierceBiotech ↗
Medtronic inks $650M deal for SPR Therapeutics
Medtronic has entered a deal to acquire SPR Therapeutics, a Cleveland-based company whose flagship product del…
May 24, 2026
CVC consortium tables $12.4bn bid to delist Italian drugmaker Recordati
DealsPharmaceutical Technology ↗
CVC consortium tables $12.4bn bid to delist Italian drugmaker Recordati
The tender offer is for €51.29 per share, representing a 13% premium on Recordati’s share price before the tak…
May 22, 2026